A recent clinical trial has demonstrated that the investigational drug ianalumab, when combined with standard therapy, significantly extends the time to treatment failure for patients suffering...
Patients with immune thrombocytopenia (ITP) who received the investigational drug ianalumab alongside standard therapy experienced significantly longer periods without treatment failure compared to those given a...
